PMC:7408073 / 0-466 JSONTXT

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T1","span":{"begin":68,"end":92},"obj":"Body_part"},{"id":"T2","span":{"begin":193,"end":217},"obj":"Body_part"},{"id":"T3","span":{"begin":219,"end":222},"obj":"Body_part"},{"id":"T4","span":{"begin":389,"end":392},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0018229"},{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0018229"},{"id":"A3","pred":"uberon_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/UBERON_0018229"},{"id":"A4","pred":"uberon_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/UBERON_0018229"}],"text":"The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients\n\nAbstract\nThe article describes the rationale for inhibition of the renin-angiotensin system (RAS) pathways as specific targets in patients infected by SARS-CoV-2 in order to prevent positive feedback-loop mechanisms. Based purely on experimental studies in which RAS pathway inhibitors were administered in vivo to humans/rodents, a reasona"}

{"project":"LitCovid-PubTator","denotations":[{"id":"4","span":{"begin":20,"end":23},"obj":"Gene"},{"id":"5","span":{"begin":24,"end":28},"obj":"Gene"},{"id":"6","span":{"begin":68,"end":73},"obj":"Gene"},{"id":"7","span":{"begin":107,"end":115},"obj":"Disease"},{"id":"25","span":{"begin":256,"end":264},"obj":"Species"},{"id":"26","span":{"begin":277,"end":287},"obj":"Species"},{"id":"27","span":{"begin":441,"end":447},"obj":"Species"},{"id":"31","span":{"begin":265,"end":273},"obj":"Disease"}],"attributes":[{"id":"A4","pred":"tao:has_database_id","subj":"4","obj":"Gene:59272"},{"id":"A5","pred":"tao:has_database_id","subj":"5","obj":"Gene:59272"},{"id":"A6","pred":"tao:has_database_id","subj":"6","obj":"Gene:5972"},{"id":"A7","pred":"tao:has_database_id","subj":"7","obj":"MESH:C000657245"},{"id":"A25","pred":"tao:has_database_id","subj":"25","obj":"Tax:9606"},{"id":"A26","pred":"tao:has_database_id","subj":"26","obj":"Tax:2697049"},{"id":"A27","pred":"tao:has_database_id","subj":"27","obj":"Tax:9606"},{"id":"A31","pred":"tao:has_database_id","subj":"31","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients\n\nAbstract\nThe article describes the rationale for inhibition of the renin-angiotensin system (RAS) pathways as specific targets in patients infected by SARS-CoV-2 in order to prevent positive feedback-loop mechanisms. Based purely on experimental studies in which RAS pathway inhibitors were administered in vivo to humans/rodents, a reasona"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T1","span":{"begin":107,"end":115},"obj":"Disease"},{"id":"T2","span":{"begin":277,"end":285},"obj":"Disease"},{"id":"T3","span":{"begin":277,"end":281},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients\n\nAbstract\nThe article describes the rationale for inhibition of the renin-angiotensin system (RAS) pathways as specific targets in patients infected by SARS-CoV-2 in order to prevent positive feedback-loop mechanisms. Based purely on experimental studies in which RAS pathway inhibitors were administered in vivo to humans/rodents, a reasona"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1177","span":{"begin":441,"end":447},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T48692","span":{"begin":457,"end":458},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients\n\nAbstract\nThe article describes the rationale for inhibition of the renin-angiotensin system (RAS) pathways as specific targets in patients infected by SARS-CoV-2 in order to prevent positive feedback-loop mechanisms. Based purely on experimental studies in which RAS pathway inhibitors were administered in vivo to humans/rodents, a reasona"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":74,"end":85},"obj":"Chemical"},{"id":"T2","span":{"begin":199,"end":210},"obj":"Chemical"},{"id":"T3","span":{"begin":219,"end":222},"obj":"Chemical"},{"id":"T4","span":{"begin":389,"end":392},"obj":"Chemical"},{"id":"T5","span":{"begin":393,"end":411},"obj":"Chemical"},{"id":"T6","span":{"begin":401,"end":411},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_2719"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_63620"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_63620"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_76932"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients\n\nAbstract\nThe article describes the rationale for inhibition of the renin-angiotensin system (RAS) pathways as specific targets in patients infected by SARS-CoV-2 in order to prevent positive feedback-loop mechanisms. Based purely on experimental studies in which RAS pathway inhibitors were administered in vivo to humans/rodents, a reasona"}

{"project":"LitCovid-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":38},"obj":"Sentence"},{"id":"T2","span":{"begin":39,"end":124},"obj":"Sentence"},{"id":"T3","span":{"begin":126,"end":134},"obj":"Sentence"},{"id":"T4","span":{"begin":135,"end":342},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients\n\nAbstract\nThe article describes the rationale for inhibition of the renin-angiotensin system (RAS) pathways as specific targets in patients infected by SARS-CoV-2 in order to prevent positive feedback-loop mechanisms. Based purely on experimental studies in which RAS pathway inhibitors were administered in vivo to humans/rodents, a reasona"}